Target intelligence / Profile preview

Aldehyde dehydrogenase 16 family member A1 (ALDH16A1)

Target
ALDH16A1
Molecular classification
Enzyme (by superfamily, though ALDH16A1 is catalytically inactive in mammals), Membrane-associated protein
01

Overview

Aldehyde dehydrogenase 16 family member A1 (ALDH16A1) is an atypical member of the aldehyde dehydrogenase (ALDH) superfamily. Unlike canonical ALDH enzymes, mammalian ALDH16A1 is catalytically inactive due to the loss of a critical active-site cysteine residue, and consequently, it does not exhibit typical aldehyde-processing activity. Nevertheless, it retains two ALDH domains and possesses several transmembrane and coiled-coil motifs, making it distinct among ALDH family proteins[1][2]. ALDH16A1 is highly expressed in the kidney and liver, where it appears to play a regulatory role in uric acid homeostasis, likely by interacting with the enzyme hypoxanthine–guanine phosphoribosyltransferase (HPRT1), modulating urate metabolism. Rare missense variants in ALDH16A1 have been associated with hyperuricemia and gout susceptibility. Additionally, ALDH16A1 interacts with maspardin, linking it to Mast syndrome, a form of hereditary spastic paraplegia. Emerging research also suggests potential non-catalytic roles in tumor biology (e.g., cell proliferation, migration, and epithelial–mesenchymal transition), and in lipid metabolism. Overall, ALDH16A1 acts primarily through protein–protein interactions rather than enzymatic activity[1][2][3][4][5].

Other names
ALDH16A1Aldehyde dehydrogenase family 16 member A1MGC10204
02

Mechanism of action

null

03

Biological functions

Modulation of urate/uric acid homeostasisPossible regulation of lipid metabolismProtein-protein interaction (notably with HPRT1 and maspardin)Potential involvement in cell proliferation and migration (tumor biology context)
04

Disease associations

Gout/hyperuricemiaCancer (particularly glioma/tumor modulation)Mast syndrome (hereditary spastic paraplegia)
05

Biomarkers

Rare missense variants (e.g., ALDH16A1*2/P527R) associated with gout/hyperuricemia susceptibility

Beyond the preview

Go deeper on Aldehyde dehydrogenase 16 family member A1 (ALDH16A1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aldehyde dehydrogenase 16 family member A1 (ALDH16A1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call